IP Library Granted Patent US 10,155,772
Granted Patent B2
US 10,155,772 · App. 15/988,498 · Granted Dec 18, 2018

Process for the synthesis of substituted morphinans

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,155,772
App. No.
15/988,498
Granted
Dec 18, 2018
Kind
B2
Abstract

The present invention relates to compounds of formula I and a process for the synthesis: The invention further relates to a process for the synthesis of 3-carboxamide substituted morphinans where a 3-cyano substituted 6-oxo substituted morphinan is reacted with a 1,3-diol.

Claims (25)

1. A process comprising the steps:

Step 1: reacting a compound having the structure

with 1,2-ethanediol to obtain a compound having the structure

Step 2: reacting the product of step 1 with a triflating agent to produce a compound having the structure

and

Step 3: reacting the product of step 2 with a source of cyanide ions in the presence of a palladium catalyst, to produce a compound having the structure

2. The process of claim 1 , further comprising the step:

Step 4: hydrolyzing the product of step 3 to produce a compound having the structure

3. The process of claim 2 , further comprising the step:

Step 5: converting the dioxalane group of the product of step 4 to a carbonyl group to produce a compound having the structure

4. The process of claim 3 , wherein step 5 is conducted in the presence of a Brönsted or a Lewis acid.

5. The process of claim 4 , wherein said acid is a mineral acid or a reagent selected from indium (III) trifluoromethanesulfonate, erbium, triflate, cerium (III) triflate, sodium tetrakis(3,5-trifluoromethylphenyl)borate and iodine.

6. The process of claim 5 , wherein said acid is hydrochloric acid.

7. The process of claim 3 , further comprising the step:

Step 6: reducing the product of step 5, thereby producing a compound having the structure

8. The process of claim 7 , wherein step 6 is carried out in the presence of zinc and ammonium chloride.

9. The process of claim 1 , wherein step 1 is conducted in the presence of a Brönsted or a Lewis acid catalyst.

10. The process of claim 9 , wherein said catalyst is selected from p-toluenesulfonic acid, tetrabutylammonium tribromide, zirconium tetrachloride and iodine.

11. The process of claim 1 , wherein step 2 is conducted in the presence of a base catalyst.

12. The process of claim 11 , wherein the base catalyst is selected from diisopropylethylamine, pyridine, N,N-dimethylaminopyridine, triethylamine and 2,6-di-t-butyl-4-methylpyridine.

13. The process of claim 1 , wherein the triflating agent is selected from 4-nitrophenyltriflate, N-phenyl bis(trifluoromethanesulfonimide), trifluoromethanesulfonic anhydride (triflic anhydride) and triflyl chloride.

14. The process of claim 13 , wherein the triflating agent is triflic anhydride.

15. The process of claim 1 , wherein the source of cyanide ions is zinc cyanide.

16. The process of claim 1 , wherein the palladium catalyst is selected from tetrakis(triphenylphosphine)palladium and tris(dibenzylideneacetone)dipalladium.

17. The process of claim 1 , wherein the palladium catalyst comprises a ligand selected from 1,1′-bis(diphenylphosphino)ferrocene (DPPF), 1,3-bis(diphenylphosphino)propane (DPPP), triphenylphosphine, 1,3-bis(diphenylphosphino)propane, 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (xantphos).

Assignments (5)
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 074858/0405 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (073213/0302) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 074858/0429 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →
RELEASE OF PATENT SECURITY AGREEMENTS Recorded Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0701 →
SECURITY INTEREST Recorded Mar 20, 2020
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 052914/0832 →